RU2018144784A3 - - Google Patents

Download PDF

Info

Publication number
RU2018144784A3
RU2018144784A3 RU2018144784A RU2018144784A RU2018144784A3 RU 2018144784 A3 RU2018144784 A3 RU 2018144784A3 RU 2018144784 A RU2018144784 A RU 2018144784A RU 2018144784 A RU2018144784 A RU 2018144784A RU 2018144784 A3 RU2018144784 A3 RU 2018144784A3
Authority
RU
Russia
Application number
RU2018144784A
Other languages
Russian (ru)
Other versions
RU2018144784A (ru
RU2751504C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018144784A publication Critical patent/RU2018144784A/ru
Publication of RU2018144784A3 publication Critical patent/RU2018144784A3/ru
Application granted granted Critical
Publication of RU2751504C2 publication Critical patent/RU2751504C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2018144784A 2016-05-19 2017-05-18 Применение карбамата для предупреждения или лечения невралгии тройничного нерва RU2751504C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061386 2016-05-19
KR10-2016-0061386 2016-05-19
PCT/KR2017/005172 WO2017200317A1 (ko) 2016-05-19 2017-05-18 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
RU2018144784A RU2018144784A (ru) 2020-06-19
RU2018144784A3 true RU2018144784A3 (enExample) 2020-08-11
RU2751504C2 RU2751504C2 (ru) 2021-07-14

Family

ID=60325324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018144784A RU2751504C2 (ru) 2016-05-19 2017-05-18 Применение карбамата для предупреждения или лечения невралгии тройничного нерва

Country Status (14)

Country Link
US (2) US11207295B2 (enExample)
EP (1) EP3459542B1 (enExample)
JP (1) JP6960415B2 (enExample)
KR (1) KR102421013B1 (enExample)
CN (1) CN109310669B (enExample)
AU (1) AU2017267160B2 (enExample)
CA (1) CA3024284C (enExample)
DK (1) DK3459542T3 (enExample)
ES (1) ES2887338T3 (enExample)
MX (1) MX389613B (enExample)
PL (1) PL3459542T3 (enExample)
PT (1) PT3459542T (enExample)
RU (1) RU2751504C2 (enExample)
WO (1) WO2017200317A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP7408643B2 (ja) * 2018-09-21 2024-01-05 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
WO2020080866A1 (ko) * 2018-10-19 2020-04-23 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DE2628420A1 (de) * 1976-06-24 1978-01-05 Bayer Ag 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide
SK57899A3 (en) * 1996-12-31 2000-05-16 Guilford Pharm Inc N-linked ureas and carbamates of heterocyclic thioesters
RU2283106C2 (ru) * 2001-02-27 2006-09-10 Орто-Макнейл Фармасьютикал, Инк. Производные карбаматов для использования для лечения боли
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4227121B2 (ja) * 2005-06-08 2009-02-18 独立行政法人科学技術振興機構 神経因性疼痛治療剤
CN102803233B (zh) * 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
CA2817290A1 (en) * 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
MA39448B1 (fr) * 2014-05-09 2019-12-31 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical

Also Published As

Publication number Publication date
KR102421013B1 (ko) 2022-07-14
CA3024284A1 (en) 2017-11-23
US11207295B2 (en) 2021-12-28
AU2017267160B2 (en) 2022-11-10
RU2018144784A (ru) 2020-06-19
JP2019516722A (ja) 2019-06-20
US20220087976A1 (en) 2022-03-24
DK3459542T3 (da) 2021-09-13
RU2751504C2 (ru) 2021-07-14
CN109310669B (zh) 2022-02-22
WO2017200317A1 (ko) 2017-11-23
BR112018073556A2 (pt) 2019-03-19
CN109310669A (zh) 2019-02-05
AU2017267160A1 (en) 2018-12-13
EP3459542A1 (en) 2019-03-27
JP6960415B2 (ja) 2021-11-05
US20190175555A1 (en) 2019-06-13
MX2018014081A (es) 2019-09-02
PT3459542T (pt) 2021-08-24
EP3459542B1 (en) 2021-06-30
ES2887338T3 (es) 2021-12-22
CA3024284C (en) 2024-01-23
PL3459542T3 (pl) 2021-12-27
MX389613B (es) 2025-03-20
EP3459542A4 (en) 2020-01-08
KR20170131241A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
BR112019009191A2 (enExample)
BR112019002665A2 (enExample)
BR112019008128A2 (enExample)
BR112019001685A2 (enExample)
RU2018144784A3 (enExample)
BR112019000402A2 (enExample)
BR202016008885U2 (enExample)
BR202016005183U2 (enExample)
CN303538992S (enExample)
CN303538642S (enExample)
CN303653682S (enExample)
CN303650592S (enExample)
CN303640735S (enExample)
CN303626040S (enExample)
CN303621695S (enExample)
CN303605226S (enExample)
CN303578579S (enExample)
CN303572639S (enExample)
CN303568081S (enExample)
CN303558214S (enExample)
CN303550590S (enExample)
CN303546742S (enExample)
CN303539078S (enExample)
CN303538996S (enExample)
CN303661397S (enExample)